aTyr Pharma is a technology company.
Translating tRNA synthetase biology into new therapies for fibrosis and inflammation.
aTyr Pharma has raised $95.0M across 4 funding rounds.
aTyr Pharma has raised $95.0M in total across 4 funding rounds.
aTyr Pharma is a clinical-stage biotherapeutics company (Nasdaq: LIFE, previously ATYR) developing first-in-class medicines from its proprietary tRNA synthetase platform to treat fibrosis and inflammation, particularly interstitial lung diseases (ILD).[1][2][4] Its lead product, efzofitimod (formerly ATYR1923), is a selective modulator of Neuropilin-2 (NRP2) that downregulates immune responses without suppression, targeting pulmonary sarcoidosis and systemic sclerosis-related ILD (SSc-ILD).[1][3][4] The company serves patients with rare immune-mediated lung disorders facing high unmet needs, solving chronic inflammation and fibrosis progression through novel extracellular signaling pathways derived from ancient tRNA synthetases.[1][4] Growth momentum includes completed enrollment in the global Phase 3 EFZO-FIT™ trial for pulmonary sarcoidosis (topline data expected Q3 2025) and ongoing Phase 2 EFZO-CONNECT™ for SSc-ILD, plus a Japan license with Kyorin Pharmaceutical.[1][4]
aTyr Pharma originated from discoveries by founder Dr. Paul Schimmel, who identified nontranslational functions of aminoacyl tRNA synthetases—essential proteins in protein synthesis that also regulate extracellular homeostasis and immune pathways.[1][4] Founded in 2005, the company emerged from this breakthrough in tRNA synthetase biology, initially exploring broader applications before focusing on fibrosis and inflammation therapeutics.[1][6] Early traction included advancing efzofitimod into clinical trials for ILD, a 2020 licensing deal with Kyorin for Japan rights, and a temporary pivot to COVID-19 respiratory trials, humanizing its mission around unmet needs in rare lung diseases.[1]
aTyr rides the wave of precision immunomodulation in biotech, targeting fibrosis—a hallmark of diseases like ILD affecting millions, amid rising demand for non-suppressive therapies post-COVID lung insights.[1][4] Timing aligns with Phase 3 readouts in 2025, capitalizing on regulatory focus on rare diseases and orphan drug incentives, while market forces favor biologics addressing unmet needs in sarcoidosis (no approved therapies) and SSc-ILD.[1][4] It influences the ecosystem by pioneering tRNA synthetase-derived drugs, potentially expanding to oncology and other inflammatory conditions, bridging evolutionary biology with modern R&D platforms.[2][5]
aTyr's trajectory hinges on efzofitimod Phase 3 topline data in Q3 2025, which could validate its platform and drive partnerships or approvals for pulmonary sarcoidosis, unlocking a first-mover advantage in ILD.[4] Trends like AI-enhanced drug discovery (echoing its "evolutionary intelligence") and fibrosis-focused M&A will shape growth, with pipeline expansion into liver fibrosis and cancer adding upside.[4][5][6] Influence may evolve from clinical innovator to commercial leader if data succeeds, tying back to its roots in Schimmel's foundational biology to redefine immune therapies for fibrosis. Risks include trial outcomes and funding in a volatile biotech market.[1][3]
aTyr Pharma has raised $95.0M in total across 4 funding rounds.
aTyr Pharma's investors include Domain Associates, Polaris Partners, Santé Ventures.
aTyr Pharma has raised $95.0M across 4 funding rounds. Most recently, it raised $49.0M Series D in July 2013.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jul 1, 2013 | $49.0M Series D | Domain Associates, Polaris Partners, Santé Ventures | |
| Oct 1, 2010 | $23.0M Series C | Domain Associates, Polaris Partners, Santé Ventures | |
| Sep 1, 2009 | $12.0M Series C | Polaris Partners | |
| Apr 1, 2007 | $11.0M Series B | Polaris Partners |